• US site
  • India site
  • Israel site
We are Venture Catalysts.
Home   »   The Canaan Team   »   Wende Hutton

Wende Hutton

General Partner  |  Menlo Park, CA  |  .(JavaScript must be enabled to view this email address)
Wende Hutton

Seasoned healthcare investor Wende Hutton is passionate about identifying, investing in and building companies that are revolutionizing the practice of medicine. She joined Canaan in 2004, bringing diverse expertise from across the entire medical spectrum. Over the last 15 years, Wende has facilitated the market entrance of over 11 novel and lifesaving medical devices, new drugs and diagnostics. Her track record is a testament to her leadership and includes the initial public offerings of five companies, of which two were later acquired, and the acquisition of four more by medical companies including the recent acquisition of BiPar Sciences, a leader in the development of a potential new class of tumor-selective drugs designed to meet the unmet needs of cancer patients.  Wende began her venture career at Mayfield Fund in 1993, where she was a General Partner in the life sciences group until 2001. During her tenure at Mayfield, Wende incubated Heartstream Inc. (HPQ) and Northstar Neuroscience Inc. (NSTR), working closely with those founding teams. Most recently, she was a General Partner at Spring Ridge Ventures, a healthcare-focused seed fund. Earlier in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing.

Wende sits on the boards of Altheos, Inc., Calibra Medical, ReVision Optics, Inc., Theraclone Sciences and Transcend Medical, Inc.  Her previous board seats include Alsius (ALUS) , Apieron, Inc. (Acquired by Aerocrine),  BiPar Sciences (acquired by Sanofi-aventis), Heartstream, Inc. (acquired by Hewlett Packard), Micro Therapeutics, Inc. (acquired by ev3, Inc.), Northstar Neuroscience (NSTR), Orquest, Inc. (acquired by Johnson & Johnson), and SenoRx, Inc. (NASDAQ: SENO).

Wende holds an AB in human biology from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar. She is an active member of several community service groups, including serving as task-force leader on obesity for the Santa Clara and Mid-Peninsula YMCAs. Beyond her community service involvements, Wende’s first love is a field biology hike or lecture.

CALIFORNIA LOCAL TIME:

Boards + Investments

Altheos, Inc.
Calibra Medical
ReVision Optics
Theraclone Sciences
Transcend Medical

Past Investments

Alsius (ALUS) (Acq. by ZOLL)
Apieron, Inc.  (Acq. by Aerocrine)
BiPar Sciences (Acq. by Sanofi-aventis)
Heartstream, Inc. (Acq. by Hewlett Packard)
Micro Therapeutics, Inc. (Acq. by ev3, Inc.)
Northstar Neuroscience (NSTR)
Orquest, Inc. (Acq. by Johnson & Johnson)
SenoRx, Inc. (SENO)

News

July 23, 2010
BiPar teaching Sanofi new tricks

July 15, 2010
Financing and Business Activity Trends Encourage Wary Optimism (Canaan News)

May 7, 2010
Wende Hutton on WSJ: Friend Or Foe? Angels, VCs Debate Who Has The Upper Hand

April 6, 2010
Altheos News on BioWorld Today: Glaucoma ROCK Inhibitor Game

April 5, 2010
Altheos completes $20 Million Series A Financing to Develop a Next-Generation Glaucoma Treatment

January 25, 2010
Wende Hutton commented on BioWorld Today: Forecast for Deal-Making Surge